As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on…

After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis…

Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own…

A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s…

After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its…

The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict…

The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics…

In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status…

A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…

Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable…

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant…